Posted by Michael Wonder on 02 Apr 2024
Solid Biosciences receives rare paediatric disease designation from the FDA for Duchenne muscular dystrophy gene therapy candidate SGT-003
1 April 2024 - Site initiations scheduled for April; patient dosing expected to begin in Q2 ,2024.
Solid Biosciences today announced that the US FDA has granted rare paediatric disease designation for SGT-003, the company’s next generation Duchenne muscular dystrophy gene therapy candidate.
